Skip to main content

Johnson & Johnson company profile

  • JNJ · NYSE
  • Healthcare
  • Pharmaceuticals
  • S&P 500
$285.75+0.79%Close 13 Nov 2026 · Market value $684.4B

About Johnson & Johnson

Johnson & Johnson is a healthcare company that researches, develops, manufactures and sells a broad range of products through two business segments: Innovative Medicine and MedTech. The Innovative Medicine segment offers prescription medicines across oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism, distributed to retailers, wholesalers, distributors, hospitals and healthcare professionals. The MedTech segment develops and manufactures procedural products in cardiovascular, orthopaedics, surgery and vision, used by physicians, hospitals, eye care professionals and clinics. The Company operates through subsidiaries in virtually all countries of the world.

A summary of the business section of the company's latest annual report, filed 11 Feb 2026.

Company facts

TickerJNJ · NYSE
SectorHealthcare
IndustryPharmaceuticals
IndexS&P 500
Fiscal year ends28 December
Reporting currencyUSD
CIK200406
Latest annual report10-K, filed 11 Feb 2026

Officers and directors

NameRoleShares ownedLatest Form 4
J. DuatoCEO and Chairman of the Board · Director1.4MOpen-market sale, 13 Aug 2026
J. TaubertEVP, WWC. Innovative Medicine748KOpen-market sale, 17 Aug 2026
T. SchmidEVP, WW Chair, MedTech161KOpen-market sale, 2 Sep 2026
M. A. WeinbergerDirector12.0KOpen-market purchase, 12 Dec 2024
J. G. MorikisDirector1.8KOpen-market purchase, 26 Nov 2025
Forminard ElizabethEVP, Chief Legal Officer—Open-market sale, 6 Aug 2026
Broadhurst VanessaEVP, Global Corp Affairs—Option exercise, 20 Jul 2026
Wengel Kathryn EEVP, Chief TO and Risk Officer—Open-market sale, 11 Jun 2026
REED JOHN CEVP, Innovative Medicine, R&D—Shares withheld for tax, 1 May 2026
Decker Robert JVP Corporate Controller—Open-market sale, 27 Feb 2026
Swanson James D.EVP, CIO—Open-market sale, 17 Feb 2026
Wolk Joseph JExec VP, CFO—Option exercise, 17 Feb 2026
Mulholland KristenEVP, Chief HR Officer—Option exercise, 15 Feb 2026

Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.

JNJ in the terminal

The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.